DF 2500
Alternative Names: DF-2500Latest Information Update: 18 Sep 2023
At a glance
- Originator Dragonfly Therapeutics
- Developer Bristol-Myers Squibb; Dragonfly Therapeutics
- Class Natural killer cell therapies; Neuroprotectants
- Mechanism of Action Immunologic cytotoxicity; Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders
Most Recent Events
- 27 Jun 2023 Preclinical trials in Neurological disorders in USA (unspecified route)